Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ELC Group Launches Clinical Trials Services

Published: Thursday, February 21, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
ELC Group now offering comprehensive range of consultancy and support services for clinical trials.

ELC GROUP has announced the launch of a new Clinical Trials service for pharmaceutical customers worldwide.

The new end-to-end service offering spans Bioavailability/Bioequivalence (BA/BE) and Phase I studies, Phase II to Phase IV and PMS studies, medical writing, Biostatistics and Statistical Programming Services, Clinical Data Management (CDM), GCP Audits and training.

The new portfolio has been developed specifically to help customers expedite the regulatory submission process and speed time to market.

For Phase I studies, ELC Group is providing its pharmaceutical customers with full regulatory consulting support, protocol design, assistance with ethics committee submissions, plus access to a Clinical Pharmacology unit and bio-analytical testing - delivered from a centre that is approved by all major regulatory agencies.

Additional services include clinical study management, method development and validation, data management, PK analysis, statistical analysis and report writing.

For Phase II to Phase IV and PMS studies, ELC Group now offers a full range of services, including study feasibility, site and investigator selection, site monitoring, project management, clinical trial supply management, and vendor management.

As part of its Clinical Trials portfolio, ELC Group is also providing expert biostatistics and statistical programming services - covering all major therapeutic areas - and delivering insights into trial design as well as developing complex statistical analysis plans.

In addition, ELC Group now offers Clinical Data Management services for early clinical development and late phase clinical development programmes, including managing data for pharmacovigilance and Pharmacokinetic/Pharmacodynamic (PK/PD) services.

The new service portfolio is rounded off with ELC Group’s Good Clinical Practice (GCP) auditing, quality assessment and risk analysis services, plus GCP training and workshops for IEC/IRB.

All services are complemented by ELC Group’s expert medical writing capability for regulatory submissions, scientific communications and medico-marketing material.

Commenting on the Clinical Trials service launch, Marco Rubinstein, CEO of ELC Group said: “With our new Clinical Trials portfolio, we are delivering a full-service solution to help ease the regulatory approval process and shorten key timelines for our customers. Our Clinical Trials services are fully customizable, and can be offered on a standalone basis or as part of our integrated full-service package, offering ultimate flexibility to our pharmaceutical customers looking to expedite product delivery and create a competitive advantage in the market.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ELC Group Expands into Pharmaceutical Product Development Market
Fast-growing regulatory affairs provider creating extensive product portfolio for sale across US, EU, LATAM, MENA and China.
Saturday, June 13, 2015
ELC Group Signs 1.5 Million Euro Regulatory Affairs Contract
Landmark deal ELC Group’s Concept to Commercialization solution approach.
Friday, May 01, 2015
ELC Group Announces Appointment of Dr. Siddharth Chachad
Internationally acclaimed clinical pharmacologist joins global regulatory affairs specialist in key management post.
Thursday, August 21, 2014
ELC Group Appoints Head of Regulatory Affairs for Russia and CIS
Inna Demidova to head new Moscow office for fast-growing global regulatory affairs specialist.
Tuesday, July 29, 2014
ELC GROUP Aim to Foster Strategic and Economic Ties Within India and China
Company visit to addresses regulatory challenges for 2012.
Wednesday, July 13, 2011
ELC Group Announces Doubled Revenues
Company set to increase expansion through acquisition.
Thursday, May 26, 2011
ELC GROUP Appoints Former TOPRA President
World-renowned physician Dr. Paolo Biffignandi joins ELC GROUP’s Advisory Board.
Friday, May 13, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos